Developing a safe and effective vaccine against the hepatitis C virus (HCV) remains a top priority for global health. Despite recent advances in antiviral therapies, the high cost and limited accessibility of these treatments impede their widespread application, particularly in resource-limited settings. Therefore, the development of the HCV vaccine remains a necessity. This review article analyzes the current technologies, future prospects, strategies, HCV genomic targets, and the governmental role in HCV vaccine development. We discuss the current epidemiological landscape of HCV infection and the potential of HCV structural and non-structural protein antigens as vaccine targets. In addition, the involvement of government agencies and policymakers in supporting and facilitating the development of HCV vaccines is emphasized. We explore how vaccine development regulatory channels and frameworks affect research goals, funding, and public health policy. The significance of international and public-private partnerships in accelerating the development of an HCV vaccine is examined. Finally, the future directions for developing an HCV vaccine are discussed. In conclusion, the review highlights the urgent need for a preventive vaccine to fight the global HCV disease and the significance of collaborative efforts between scientists, politicians, and public health organizations to reach this important public health goal.
In the current modern era of unhealthy lifestyles, non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and has become a serious global health problem. To date, there is no approved pharmacotherapy for the treatment of NAFLD, and necessary lifestyle changes such as weight loss, diet, and exercise are usually not sufficient to manage this disease. Patients with type 2 diabetes mellitus (T2DM) have a significantly higher risk of developing NAFLD and vice versa. Sodium–glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic agents that have recently been approved for two other indications: chronic kidney disease and heart failure in diabetics and non-diabetics. They are also emerging as promising new agents for NAFLD treatment, as they have shown beneficial effects on hepatic inflammation, steatosis, and fibrosis. Studies in animals have reported favorable effects of SGLT2 inhibitors, and studies in patients also found positive effects on body mass index (BMI), insulin resistance, glucose levels, liver enzymes, apoptosis, and transcription factors. There are some theories regarding how SGLT2 inhibitors affect the liver, but the exact mechanism is not yet fully understood. Therefore, biomarkers to evaluate underlying mechanisms of action of SGLT2 inhibitors on the liver have now been scrutinized to assess their potential as a future in-label therapy for NAFLD. In addition, finding suitable non-invasive biomarkers could be helpful in clinical practice for the early detection of NAFLD in patients. This is crucial for a positive disease outcome. The aim of this review is to provide an overview of the most recent findings on the effects of SGLT2 inhibitors on NAFLD biomarkers and the potential of SGLT2 inhibitors to successfully treat NAFLD.
The interrelationship between periodontitis and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has attracted increasing attention due to the significant global rise in the prevalence of both conditions. Periodontitis, a chronic inflammatory disease, affects a substantial portion of the population and parallels the growing incidence of MASLD, which currently impacts nearly 30% of the global population. The updated nomenclature reflects a deeper understanding of the condition’s metabolic origins. This narrative review focuses on the shared pathophysiological mechanisms, particularly systemic inflammation, insulin resistance, and oxidative stress that may underlie the bidirectional relationship between these diseases. These mechanisms often act in concert to promote disease development. Unlike previous literature, this review emphasizes the hypothesis that chronic periodontal inflammation may not only mirror but also contribute to the systemic metabolic dysregulation observed in MASLD. We critically assess current evidence supporting this link by highlighting the role of inflammatory mediators in bridging oral and hepatic health, and by proposing an integrated, multidisciplinary approach to its early detection and management. The aim is to offer novel insights that can help develop better prevention strategies and more effective treatments for both diseases.
Synthetic calcium phosphates have been tested in randomised trials of sinus augmentation and ridge preservation but rarely in ridge augmentation. To our knowledge, the augmented volume of biphasic calcium phosphate (BCP) mixed with autogenous bone has not been measured clinically in non-contained ridge defects. We grafted four such maxillary defects with BCP (RESORBA Synthetic Bone, hydroxyapatite/β-tricalcium phosphate 60/40; S1, S2) or porcine xenogeneic mineral (RESORBA Xenogenic Bone Graft; X1, X2), each mixed 50:50 with scraper-harvested autogenous chips, under a native collagen membrane (PARASORB RESODONT Forte). Cone-beam computed tomography volumetry gave the net radiodense volume (new bone and residual graft) in a fixed 10 × 10 mm window, with measurement envelopes over analysis choices. All four sites healed uneventfully and received implants, with the graft (S1, X1) or at re-entry (S2, X2), S2 with 2 mm of buccal hard tissue despite loose particles outside the contour. All were uneventful for 13–65 months after grafting, apart from one resolved sinus tract in X1. Volumes (mm3, envelopes in brackets) were 99.7 (91.8–112.3) in S1 and 137.0 (127.6–150.8) in X1, their envelopes overlapping before the post hoc changes, and 95.4 (82.3–99.5) in S2 and 267.1 (261.4–272.3) in X2, apart before and after them. As each volume difference is also one between patients and sites, none is attributed to the substitute.